Category: Blog

GHK-Cu Pharmacology Studies — Mechanisms & Research

GHK-Cu pharmacology studies show copper peptides activate tissue repair pathways at concentrations as low as 1 nanomolar — mechanisms backed by 40+ years

GHK-Cu Dose Response Research — Clinical Evidence

GHK-Cu dose response research shows peak tissue repair at 1–10 ng/ml, with diminishing effects above 10 ng/ml and potential cytotoxicity beyond 1000 ng/ml.

GHK-Cu Long Term Studies — What the Research Shows

GHK-Cu long term studies show promising tissue repair and anti-inflammatory effects, though multi-year human trials remain limited. Here’s what we know in

GHK-Cu Safety Studies — Clinical Evidence Review

GHK-Cu demonstrates excellent safety across 40+ clinical studies with zero serious adverse events at therapeutic doses. What the human trial data actually

Sermorelin Study — Clinical Evidence & Research Findings

Sermorelin study data shows 15–30% IGF-1 increases within 3–6 months. Explore clinical trials, research-grade synthesis quality, and mechanisms driving

GHK-Cu Comparative Studies — What Research Really Shows

GHK-Cu comparative studies reveal 30% faster wound healing vs controls and enhanced collagen synthesis across clinical trials. Evidence-backed analysis of

GHK-Cu Mechanism Studies — Cellular Repair Insights

GHK-Cu mechanism studies reveal how this tripeptide activates tissue repair genes, modulates copper metabolism, and triggers wound healing pathways at the

Top Sermorelin Studies — Research Findings & Clinical Data

The top sermorelin studies show 14–20% IGF-1 increases in adults with deficiency, with Phase III trials establishing safety across 200+ subjects over 18

Sermorelin Animal Research — Mechanisms, Models & Findings

Sermorelin animal research reveals GH-pulse restoration in rodents and primates, driving peptide development. Mechanisms, models, and translational

Sermorelin Dose Response Research — What Scientists Found

Sermorelin dose response research shows linear GH increases up to 1mcg/kg — higher doses don’t improve outcomes. Analysis of clinical trial data reveals